Analysts forecast that TG Therapeutics Inc (NASDAQ:TGTX) will announce $40,000.00 in sales for the current quarter, Zacks reports. Two analysts have made estimates for TG Therapeutics’ earnings. TG Therapeutics also reported sales of $40,000.00 during the same quarter last year. The firm is expected to issue its next quarterly earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that TG Therapeutics will report full year sales of $170,000.00 for the current fiscal year, with estimates ranging from $150,000.00 to $200,000.00. For the next fiscal year, analysts forecast that the firm will report sales of $19.08 million, with estimates ranging from $150,000.00 to $52.99 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.01. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million.
A number of large investors have recently bought and sold shares of the business. venBio Select Advisor LLC boosted its holdings in TG Therapeutics by 13.1% in the fourth quarter. venBio Select Advisor LLC now owns 4,750,000 shares of the biopharmaceutical company’s stock valued at $19,475,000 after purchasing an additional 549,969 shares during the last quarter. BlackRock Inc. boosted its stake in shares of TG Therapeutics by 2.2% during the 4th quarter. BlackRock Inc. now owns 4,519,331 shares of the biopharmaceutical company’s stock worth $18,529,000 after acquiring an additional 98,479 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of TG Therapeutics by 9.6% during the 3rd quarter. Vanguard Group Inc now owns 3,058,080 shares of the biopharmaceutical company’s stock worth $17,125,000 after acquiring an additional 268,483 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of TG Therapeutics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,058,080 shares of the biopharmaceutical company’s stock worth $17,125,000 after acquiring an additional 268,483 shares in the last quarter. Finally, Great Point Partners LLC boosted its stake in shares of TG Therapeutics by 53.8% during the 4th quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $12,300,000 after acquiring an additional 1,050,000 shares in the last quarter. 55.26% of the stock is currently owned by institutional investors.
Shares of TGTX opened at $6.92 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 2.03 and a current ratio of 1.72. TG Therapeutics has a 12 month low of $3.32 and a 12 month high of $16.00.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Further Reading: What is a Derivative?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.